Mechanisms Promoting Chronic Lung Diseases: Will Targeting Stromal Cells Cure COPD and IPF? by Lynne A. Murray & Cory M. Hogaboam
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Mechanisms Promoting Chronic Lung 
Diseases: Will Targeting Stromal  
Cells Cure COPD and IPF? 
Lynne A. Murray1 and Cory M. Hogaboam2 
1Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, 
2Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 
1UK 
2USA 
1. Introduction 
Tissue remodeling is a common pathology in many diseases. The reparative processes of 
wound healing result in an increase in extracellular matrix (ECM) generation, serving to 
restore barrier protection and normal tissue architecture. However in the lung, increased 
formation of ECM results in decreased lung compliance and impaired gas exchange. The 
chronic lung diseases COPD (chronic obstructive pulmonary disease) and IPF (idiopathic 
pulmonary fibrosis) both exhibit increased extracellular matrix (ECM) deposition within the 
lung due to increased stromal cell number and activation. The chronic nature of the disease 
is hypothesized to correlate with the extent of scarring and remodeling, with greater 
evidence being available for COPD rather than IPF. The potential underlying causes of both 
diseases are numerous, including direct insults to the lung such as cigarette smoke or 
exhaust particles; as well as underlying autoimmune conditions such as scleroderma or 
collagen vascular disease. Moreover, a correlation between COPD and smoking is well 
established; however, any causes for IPF, apart from a familial link, are currently not 
understood. To date there are no approved anti-fibrotic therapies that target the underlying 
remodeling in either disease. In order to treat this pathology, understanding the 
mechanisms promoting continual ECM deposition may elucidate novel therapeutic 
approaches that could provide clinical benefit to patients suffering from these debilitating 
diseases. This Chapter will focus on the cellular mechanisms and interactions within the 
fibrotic lung including resident fibroblast-epithelial cells as well as the cross-talk between 
fibroblasts and recruited bone marrow derived cells such as fibrocytes and monocytes. Also, 
the soluble mediators that have been associated with disease and how these can directly and 
indirectly modulate stromal cell activation will be discussed. 
2. COPD and IPF disease pathogenesis  
One of the common features between COPD and IPF is the heterogeneous pathology 
observed in the lung at the macroscopic level in both disease settings. Both diseases exhibit 
patchy areas of pathology, consisting of ECM proteins or inflammatory infiltrates, with 
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fibrotic regions being juxtaposed to regions of normal alveolar tissue or areas with 
interstitial leukocyte accumulation. Grossly, COPD contains regions dense in bronchiolar 
inflammation and consolidated lung tissue, as well as emphysematous areas, due to alveolar 
destruction 1,2. In IPF, salient hallmarks of disease included profound collagen deposition, as 
well as regions of honeycombed lung due to a collapse of alveolar walls 3. COPD has been 
clinically separated into distinct GOLD (Global initiative for chronic Obstructive Lung 
Disease) Stages based primarily on a key parameter of lung function, Forced Expiratory 
Volume in one second (FEV1). Here, patients with more significant impairment in FEV1 have 
a higher GOLD Stage status. Supporting these changes in lung function analysis of the 
underlying pathologies of patients within each GOLD Stage has also highlighted that, as the 
disease progresses, there is an increase in airway wall thickness 4. Even though the GOLD 
staging system is universally recognized, there are efforts underway to also separate COPD 
patients in to fast decliners and slow decliners based on lung function parameters. Extensive 
work is currently underway to try and stage IPF in an equivalent manner. In this disease, 
retrospective analysis of patient survival has indicated that there is both a rapidly 
progressing phenotype and a more slowly progressing phenotype of IPF patients. In the 
‘rapid’ IPF progressors, approximately 50% of patients will die within 6-8 months, whereas 
this is greatly extended in slow progressors 5,6.  
Chronic remodeling is a common feature between IPF and COPD. In order to understand 
the mechanisms underlying the maintenance, progression and staging of disease, this Book 
Chapter will focus on the similarities and differences between stromal cells in these patients. 
We will focus on the phenotypic differences in fibroblasts and myofibroblasts as well as how 
these cell types interact within the lung (Fig. 1). We will also describe some of the key 
families of mediators that are found to be elevated in disease and how their mechanism may 
be directly promoting chronic lung disease. Lastly, we will discuss the potential therapeutic 
approaches to targeting stromal cells clinically. 
3. Profibrotic role of fibroblasts  
Fibroblasts play a myriad of important roles in normal tissue function. In the lung they 
coordinate organogenesis and budding of the lung from the foregut through intimate bi-
directional communication with adjacent epithelial cells. Myofibroblasts are “smooth 
muscle-like cells” that are morphologically similar to fibroblasts, but also express alpha-
smooth muscle actin (-SMA) 7. Fibroblasts and myofibroblasts are also key cells in the 
production and homeostatic maintenance of the ECM of the tissue or organ in which they 
reside. They are metabolically active cells, capable of synthesizing and secreting ECM 
components such as collagens and proteoglycans. Fibroblasts continually synthesize ECM 
proteins although the amount they secrete is tightly regulated, with up to 90% of all 
procollagen molecules being degraded intracellularly prior to secretion, depending on tissue 
and age. Further, fibroblasts generate both matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases, thus controlling homeostatic tissue architecture.  
Myofibroblasts were first described by Gabbiani and colleagues as cells central to wound 
healing 8. The actin filaments result in myofibroblasts having contractile properties, which, 
at sites of wound healing serve to close the wound. However, the presence of contractile 
myofibroblasts in the interstitium of the lung may cause a retraction of parenchymal tissue 
resulting in alveolar collapse giving the characteristic honeycombing as observed in the 
lungs of IPF patients, or add to the increase in alveolar size, which is characteristic of COPD 9.  
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Fig. 1. Cellular Pathways in Lung Fibrosis: Multi-Faceted Aberrant Response 
Chronic lung remodelling is hypothesized to occur following repeated trauma or injury to 
the lung. Multiple cellular pathways and interactions which can all promote ECM 
deposition have been described in lung fibrosis which promote fibroblast and myofibroblast 
activation, proliferation and survival. Following injury to the epithelium, apoptotic and 
necrotic signals stimulate collagen producing cells. These resident epithelial cells can also 
differentiate into a collagen-producing phenotype during EMT. The immune response in the 
lung is also altered in chronic lung diseases, with pro-fibrotic M2 macrophages and type 2 T 
cells predominating. These cells generate soluble mediators such as TGF, CCL2 and IL13 
which directly activates collagen producing cells. 
Key: EMT: epithelial to mesenchymal transition; Mac: Macrophage; Treg: regulatory T cell 
Under normal conditions, myofibroblasts sequentially perpetuate and then dampen 
inflammation via the secretion of chemokines, cytokines, arachidonic acid metabolites and 
protease inhibitors. When activated, they express cell surface adhesion molecules allowing 
specific interactions with immune and inflammatory cells, including lymphocytes, mast 
cells and neutrophils. If these processes become dysregulated, fibrosis may ensue with 
catastrophic consequences for lung function. 
Most insight into the potential role of fibroblasts at driving pulmonary remodeling, as well 
as phenotypic differences in fibroblasts found in fibrotic regions versus those located in 
normal tissue has been garnered from in vitro studies using fibroblasts isolated from IPF 
lungs and animal models. Fibroblasts isolated from fibrotic environments are 
phenotypically different than non-fibrotic fibroblasts 10-12. Fibroblasts from a profibrotic 
environment exhibit altered responsiveness to growth factors, express enhanced receptor 
levels for chemokines, which has also been observed in murine models of pulmonary 
remodeling. These studies suggest a distinct heterogeneity in fibroblast function and 
phenotype in the fibrotic lung.  
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We and other investigators have reported that fibroblasts derived from IPF lungs proliferate 
faster than cells derived from normal lung tissue. In contrast, others have shown that the 
growth rate of IPF fibroblasts was significantly slower than normal fibroblasts. This 
discrepancy may be due to the site in the lung from which fibroblasts are harvested, since 
the magnitude of inflammation and fibrosis are heterogeneous in distribution. Thus, areas of 
active fibrosis may yield hyperproliferative fibroblasts compared to areas of established 
fibrosis in which cells may be hypoproliferative. 
To begin to address this diversity, recent studies have used microarray technologies to 
profile global gene expression in pulmonary fibrosis in man and mouse models. These 
studies have showed expression of almost 500 genes are increased more than two- fold in 
fibrotic lungs, including many genes related to cytoskeletal reorganization, ECM, cellular 
metabolism and protein biosynthesis, signaling, proliferation and survival 13,14. There was 
excellent concordance between gene expression in human and experimental models, giving 
us some confidence in the value of our efforts to model human disease. Studies examining 
human lung fibroblast global gene expression in response to TGF1 have shown almost 150 
genes upregulated, representing several functional categories described above. This 
included 80 genes that were not previously known to be TGF -responsive.  
The progression and severity of many lung diseases, most notably IPF, are tightly associated 
with regions of fibroblast accumulation and proliferation, to the extent that these regions have 
become a reliable indicator of survival. The increased number of (myo)fibroblasts seen in these 
diseases, implies that they are either hyper-proliferative and/or resistant to apoptosis. 
However, most studies suggest that these cells proliferate faster than normal 10,15,16 
4. Sources and fates of fibroblasts and myofibroblasts  
As remodeling of the lung is associated with accumulation and activation of fibroblasts and 
myofibroblasts, the derivation of both cell types is currently under examination. Reports 
indicate that there may be multiple pathways through which fibroblasts and myofibroblasts 
are derived 17. Fibroblasts isolated from human or murine fibrotic tissue exhibit enhanced 
basal proliferation. Therefore an increase in the fibroblast pool could be due to local 
proliferation. Myofibroblasts express a panel of markers and these markers have been 
correlated with site of derivation. For example, myofibroblasts found in the peripheral and 
subpleural regions of fibrosis express -SMA, vimentin and desmin, whereas cells found in 
other regions of the lung do not express desmin 18.  
4.1 Epithelial to mesenchymal transition 
Another potential source of fibroblasts is by a process called epithelial to mesenchymal 
transition (EMT). EMT is a dynamic process by which epithelial cells undergo phenotypic 
transition to fully differentiated motile mesenchymal cells, such as fibroblasts and 
myofibroblasts. This process occurs normally during early fetal development where there is 
seamless plasticity between epithelial and mesenchymal cells 19. Furthermore, this 
phenomenon is well accepted in cancer as a key mechanism that supports tumor metastases 20. 
However, the process of EMT in development and cancer differ greatly in that, unlike 
developmental EMT, the tumorigenic EMT process is poorly regulated 21. During the process 
of EMT, the downregulation of epithelial and tight junction proteins is associated with a 
concomitant increase in mesenchymal cell markers 22,23. In chronic lung diseases, the dual 
expression of epithelial and mesenchymal markers in the same cells has led investigators to 
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postulate that EMT is a mechanism resulting in more ECM-generating mesenchymal cells in 
the lung  24,25. The differentiation of airway epithelial cells has been previously described, for 
example, type I pneumocytes transitioning into goblet cells 26-29. However, the switching of an 
epithelial cell into a phenotype that moves beyond the original cell’s embryonic lineage, has 
only recently been suggested to be a causative factor in fibrosis 23,30,31.  
The initial events of EMT include the loss of cell polarity and the induction of matrix 
metalloproteinases (MMPs) that promote basement membrane degradation and cell 
detachment. The cells also undergo cytoskeletal changes, as well as altered expression of 
surface molecules which allow for the migration and transition of these cells to a mesenchymal 
phenotype 32,33. The majority of the work evaluating EMT has been performed in vitro; 
however the full extent of this pathogenic pathway in vivo is currently being evaluated. In 
animal models of kidney fibrosis, it has been estimated that up to 20% of the fibroblasts found 
in the fibrotic lesions were derived from the epithelium through EMT 30,34-37.  
The idea of EMT promoting the fibrosis observed in COPD and IPF is rapidly beginning to 
evolve 29. Several recent studies have also shown that EMT occurs in lung epithelial cells 
both in vitro and in vivo, supporting the concept of EMT contributing to the fibrosis observed 
in IPF 29,38,39. Moreover, we have recently published an alteration in the microRNA 
regulation of genes associated with EMT in IPF40. The potential of EMT promoting COPD 
requires further investigation. Nevertheless, there is an emerging link between COPD and 
lung cancer, thus increasing the likelihood of EMT being present in the COPD lung. The link 
between smoking, lung cancer and COPD is also apparent, in that smoking is a risk factor 
for COPD and also for lung cancer 41,42. An underlying response to cigarette smoke is 
generating an altered inflammatory environment in the lung 43, which can then be 
susceptible to either COPD or lung cancer development 44. Therefore, future work 
correlating the timecourse of EMT induction with COPD and IPF disease staging will be 
insightful to determine the extent of contribution mediated by this process.  
4.2 Circulating progenitor mesenchymal cells 
Along with the epithelium, studies have also highlighted a role for bone marrow-derived 
circulating progenitor mesenchymal cells, or fibrocytes, in promoting lung fibrosis by 
differentiating into fibroblasts or myofibroblasts 45,46,47 (Fig. 1). Fibrocytes have been 
observed at sites of active fibrosis and increased numbers of these cells in the circulation 
correlate with mortality in IPF 5. They are induced by pro-fibrotic mediators such as TGF1 
and Th2 cytokines 48; and the cell markers include leukocyte markers (CD45, CD34), 
mesenchymal markers (collagen I, fibronectin) and chemokine receptors (CCR3, CCR5, 
CCR7 and CXCR4) 49. Human and mouse studies have demonstrated that fibrocytes from 
peripheral blood migrate to skin wound chambers 49-51 and bronchial mucosa after antigen 
challenge 52. Furthermore, these cells have been reported in disease states with fibrotic 
pathologies including hypertrophic scars, asthma and IPF 52-55.  
Fibrocytes are pleiotropic and may contribute to fibrogenesis by directly producing collagen, 
as well as inflammatory cytokines, hematopoietic growth factors, and chemokines 54-58 (Fig. 
2). In a study performed in collaboration between AstraZeneca and Malmö University 
Hospital, increased fibrocyte numbers were observed in the circulation of COPD patients, 
where patients with mild COPD had the most elevated number of fibrocytes in comparison 
to moderate COPD, severe COPD or healthy patients 59. Although there was no correlation of 
fibrocyte number with any lung function parameter, inhaled glucocorticosteroid use  
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Fig. 2. Overlapping Differentiation Pathways and Functions of Fibroblasts, Fibrocytes and 
Macrophages 
Fibroblasts, fibrocytes and macrophages share many in vitro and in vivo functions such as 
mediator production, host defence and extracellular matrix deposition. Monocytes can 
differentiate into fibrocytes or macrophages depending on the environment and the nature 
of the stimulus. In vitro studies have highlighted a role for various mediators such as 
cytokines, TLR signals, cellular debris and cell function at promoting differentiation. 
However, it is likely a combination of these pathways in situ which dictates the fate of the 
monocyte. Fibrocytes have been shown to differentiate into fibroblasts, in part through 
losing CD45 expression but retaining collagen I expression. Moreover in vitro, fibrocytes 
stimulated with TGF or ET-1 can promote fibrocyte to fibroblast differentiation. Recent 
evidence has indicated that fibroblasts can differentiate into haematopoietic cells when 
stimulated with appropriate growth factors.  
Key: TGF: transforming growth factor ; GM-CSF: granulocyte macrophage colony-
stimulating factor; M-CSF: macrophage colony-stimulating factor; TLR: toll-like receptors; 
ET-1: endothelin-1; OCT4: octamer-binding transcription factor 4); ECM: extracellular 
matrix; SMA: -smooth muscle actin. 
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significantly inhibited circulating fibrocyte numbers, corroborating the pro-inflammatory 
association of fibrocytes 59. While it was originally thought that fibrocytes promote fibrosis 
through production of ECM components, it is becoming increasingly hypothesized that their 
primary role in tissue remodelling may be through secretion of soluble factors. 
Fibrocytes have pleuripotent potential to differentiate into other cell lineages, as has been 
demonstrated with fibrocyte-derived adipocytes 60. Furthermore, the extreme plasticity of 
these cells in vitro, makes both the derivation and characterization of these cells difficult. 
Exposure of fibrocytes to TGF1 in vitro results in the cells transitioning into a myofibroblast 
phenotype that expresses both fibronectin and type III collagen 52. Using an adoptive 
transfer model of bone marrow cells from green fluorescent protein (GFP) transgenic mice 
into mice challenged with intratracheal bleomycin to initiate lung injury, recruited GFP+ 
fibrocytes were shown to differentiate into fibroblasts while resident lung fibroblasts 
differentiated into myofibroblasts 56.  
At sites of normal wound healing, once sufficient ECM has been deposited, fibroblasts and 
myofibroblasts undergo apoptosis 61,62. This serves to limit the excessive deposition of ECM 
and also dampen the pro-inflammatory and pro-fibrotic milieu. However, myofibroblasts 
persist in fibrotic conditions. Moreover, IPF fibroblasts are relatively resistant to apoptosis in 
vitro, with IPF cells inducing a different pattern of pro-apoptotic enzymes in response to 
Fas-L stimulation compared to normal fibroblasts 63. 
A recently described study showed an alternate potential fate of fibroblasts in that they can 
de-differentiation or transition into haematopoietic cells64. Here the investigators showed 
that, in the presence of haematopoietic transcription factors, fibroblasts can convert into 
haematopoietic progenitor cells, indicating a stem-like potential of cells that have 
traditionally thought to be resident to the lung 64. Therefore, expanding our understanding 
on the pathways that control fibroblast to myofibroblast fate, as well as fibroblast to non-
fibroblast cell fate, particularly in disease, will greatly expand our understanding of disease.  
5. Fibroblast cell: Cell interactions  
In the lung, fibroblasts are found in the greatest number in the subepithelial layer of the 
conducting airways and the interstitium of the lung parenchyma (Fig. 1). Here they are in a 
prime location to interact with the epithelial and endothelial cells, as well as leukocytes in 
the airspaces, interstitium and vasculature. One of the key inflammatory cells that is found 
in the lung, and one that is becoming more associated with the maintenance and 
progression of fibrosis, is the alternatively activated (M2) macrophage. The M2 macrophage 
is the predominant macrophage found in the lungs of IPF patients 65. Moreover, M2 
macrophages have been associated with COPD 66,67. In healthy tissue, alveolar macrophages 
are known to remove apoptotic and necrotic debris and pathogens via phagocytosis in a 
non-phlogistic mechanism, in that downstream inflammation is limited and the 
inflammatory process is attenuated 68.  
In chronic lung disease, the predominant M2 macrophage phenotype is inefficient at 
clearing debris. M2 macrophages are defective in phagocytosis and do not dampen the 
inflammatory response 69. These macrophages are capable of synthesizing pro-fibrotic 
mediators, which supports their role in wound healing, yet this cell type is inefficient at 
supporting host defense 69. This may explain why COPD and IPF patients are susceptible to 
repeated bouts of pulmonary infections or exacerbation of disease. These cells express 
elevated levels of scavenger receptors such as macrophage scavenger receptor (MSR) and 
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mannose receptor C (MRC/ CD206) 69,70. Assessing circulating primary cells from IPF 
patients, we have determined an elevation of CD163+CD14+ cells and M2-associated soluble 
mediators in the circulation, which was more pronounced in progressive IPF patients, 
suggestive of an overall elevated M2 background in these patients 71. We have also shown 
that peripheral blood monocytes from patients with scleroderma-related lung disease 
display a pro-fibrotic phenotype, characterized by increased CD163 expression and CCL18 
production 72. Interestingly, macrophages in the lungs of COPD patients, as well as smokers 
with or without COPD, also demonstrate a skewing towards an M2 phenotype, with a 
deactivated M1 phenotype 73,74. Moreover in vitro, cigarette smoke induces a M2-type 
phenotype and this result was also seen in an in vivo cigarette smoke model in mice 73. In 
vitro, macrophage polarization to an M2 phenotype has only been shown robustly with 
mouse cells. Here the differentiation of a monocyte to an M2 phenotype requires a cocktail 
of cytokines including IL13 and CCL17/TARC75. Therefore the Th2 cytokine profile 
observed in remodeled lungs contributes to the appearance of M2 macrophages.  
Studies of bleomycin-induced fibrosis have assessed either M2 macrophage or fibrocyte 
number 71,76. It is increasingly recognized that there is some overlap between these cell subsets 
in terms of both function and markers 76. However, although both fibrocytes and M2 
macrophages can be derived from monocytes, they are not completely redundant in function. 
Recently, using a lung-specific TGF1 over-expression model of lung fibrosis, we determined 
that depletion of lung monocyte/macrophages using liposomal clodronate reduced collagen 
accumulation, but this had no effect on the TGF-induced fibrocyte recruitment 77. Therefore, 
for novel therapeutic approaches such as cell depletion or specific targeting, the M2 
macrophage may be a more compelling target for chronic lung remodeling.  
In COPD, alveolar macrophages have been hypothesized to have reduced anti-inflammatory 
properties, as well as a reduced capacity to turn over matrix 78. However a recent study 
looking at macrophage number, MMP expression and emphysema determined a correlation 
between a greater infiltration of macrophage to the lung and emphysema in COPD patients 79. 
Ex vivo, cigarette smoke induces a wide array of changes in the inflammatory profile and the 
host defence potential of COPD alveolar macrophages 80. Moreover, microarray analysis 
indicated a correlation between alveolar macrophage gene expression, circulating monocyte 
gene expression and lung function 81. The investigators hypothesized that there is a “COPD-
related gene expression pattern” as many genes differentially expressed in COPD alveolar 
macrophages were also expressed in COPD circulating monocytes 81. 
6. Activators of fibroblasts/ mesenchymal cells  
Fibroblasts are activated by numerous signals including: mechanical forces such as those 
imposed during bronchoconstriction; matrix interactions; hypoxia and resultant changes in 
pH levels; and soluble mediators (Fig. 1). The large variety of soluble mediators capable of 
activating mesenchymal cells are produced by many different cell types found in fibrotic 
regions. Furthermore, proteases of the coagulation cascade and other serum factors also 
promote fibroblast proliferation, collagen synthesis, migration and differentiation.  
6.1 Growth factors 
Growth factors are the most recognized mediators that activate mesenchymal cells. 
Transforming growth factor β (TGFβ) is one of the most potent profibrotic mediators in vitro 
and is a central driver in the remodeling process. TGF1 regulates numerous biologic 
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activities such as proliferation, apoptosis, and differentiation 82,83. TGF1 is upregulated in 
the lungs of IPF patients and patients with other chronic lung diseases 84-89. Interestingly, 
expression of TGF1 is nearly absent in the bronchial epithelial cells but is highly expressed 
in inflammatory cells beneath the basement membrane where subepithelial fibrosis 
predominates 90. In COPD, TGF has also been reported to be produced by circulating and 
interstitial T cells and monocytes 91. Polymorphisms in the promoter region of TGF1 have 
been reported in COPD patients 92. However, TGF SNPs have been associated with 
protection in COPD 93 or have been linked to COPD but not related to worsening of disease 94.  
Transient overexpression of TGF1, or pulmonary delivery of this cytokine to mouse lungs, 
induces a pronounced interstitial fibrosis mediated by excess ECM generation and 
deposition, as well as the presence of myofibroblasts95. Using a transgenic mouse model of 
SMAD-3 deficiency, TGF/SMAD-3 signaling has been shown to be required for alveolar 
integrity and ECM homeostasis and that this pathway is involved in pathogenic 
mechanisms mediating both tissue destruction and fibrogenesis.  
Due to TGF1 being such a potent growth factor, the release and activation of this growth 
factor is tightly regulated. TGF is released in a latent complex, associated with LAP 
(latency activated peptide) and LTBP. There are several mechanisms by which TGF is then 
activated and these include integrin-mediated cell cytoskeletal rearrangement in the case of 
integrin v696; cell membrane MMP recruitment for enzymatic cleavage in the case of 
integrin v897 and other protease-related mechanisms exhibited by components of the 
coagulation cascade98 (discussed later). The integrin v6 is upregulated in IPF99 and 
neutralization of this integrin in vivo reduces fibrosis in various experimental models 99-101.  
There are also endogenous inhibitors of TGF, the largest being the BMP (bone 
morphogenic protein) family. The BMP family is structurally and functionally related to the 
TGF superfamily 102. BMPs inhibit TGF signaling through either inhibiting Smad 2/3 
phosphorylation or competing for Smad 4 or both 103,104. Recombinant BMP7 has been 
shown to inhibit TGF-induced EMT in vitro, as well as reducing renal fibrosis 105. However, 
we have shown that BMP7 had no anti-fibrotic effect in models of lung fibrosis, nor were 
there effects on lung epithelial cells in vitro 106. 
6.2 Th2-associated mediators 
Interleukin 13 (IL13) and IL4 are two pleiotropic, Th2-associated cytokines, with numerous 
distinct and overlapping functions. They share overlapping roles due to the shared IL13R1 
receptor subunit. However they also have unique subunits that confer the distinct functions. 
IL13 activates epithelial cells and goblet cells causing mucous production, goblet cell 
hyperplasia and EMT 107,108. Various animal models of pulmonary fibrosis have indicated a 
more pro-fibrotic role for IL13 than IL4. Indeed it has been hypothesized that IL4 is involved 
in the initiation of fibrosis whereas IL13 is central to the maintenance of the fibrotic 
response.  
We have published that IL-13 is elevated in the lungs of IPF patients 71 and this protein is 
associated with fibrotic pathologies and aberrant remodeling at various tissue sites 65,109. 
There is also elevated expression of the two IL13 receptor subunits IL13R1 and IL13R2 
which are prominant on fibroblasts 110,111. More recently we have shown that IPF fibroblasts 
are hyper-responsive to IL13 in comparison to non-fibrotic fibroblasts58. It was originally 
hypothesized that IL13R2 is a decoy receptor as it has a short cytoplasmic tail and although 
it is the higher affinity receptor subunit, it is found at high levels in a soluble form, but only 
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in murine models of fibrosis112 and not in humans113. However, recent data has suggested 
that signaling of IL13 through IL13R2 is pro-fibrotic, resulting in TGF1 production 114.  
Lung-specific over-expression of IL13 in mice results in remodeling and emphysema 115. 
Moreover, various MMPs and cathepsins that are associated with COPD1 are also induced in 
the IL13-transgenic lung 116. However robust detection of IL13 has not been consistently 
reported. IL13 producing macrophages and NKT cells have been detected in the COPD lung 
117. Also, the presence of the cytokine and IL13 positive cells have been shown in the bronchial 
epithelium of smokers with chronic bronchitis 118. In contrast, decreased IL13 has been 
measured in emphysema compared to non-emphysematous lungs 119. An inverse correlation 
between plasma IL13 and the lung diffusion capacity for carbon monoxide (DLCO) parameter, 
used to determine the efficiency  of gas exchange in COPD has been reported 120. 
Another Th2-associated mediator that is being actively researched in fibrosis is the chemokine 
CCL18/ PARC. In IPF, CCL18 has been associated with poor outcome, namely, patients with 
CCL18 levels greater than 150ng/ml in the circulation will typically have more progressive 
disease, compared to those with CCL18 levels below 150ng/ml 6. CCL18 expression is also a 
marker for M2 macrophages 121, therefore linking the profibrotic cell phenotype with IPF 
progression. In the recent ECLISPE study, elevated CCL18 levels in COPD patients has been 
associated with increased chance of COPD exacerbation 122. This association of CCL18 with 
COPD exacerbations was in stark contrast to TNF, IL6 or CXCL8/ IL8 levels, or the number 
of pack years of smoking 122. These observations may change the understanding of the 
pleiotropic nature of the underlying mechanisms for COPD, as CCL18 is not associated with 
smoking or with neutrophil accumulation and activation.  
6.3 Coagulation cascade 
Thrombin is a serine protease generated during activation of the coagulation pathway 123. 
Thrombin has been implicated in a number of pulmonary fibrotic diseases such as acute 
lung injury (ALI) 124,125 acute respiratory distress syndrome (ARDS) 126, interstitial lung 
disease (ILD) 127,128  and IPF 127,129-132 and IPF BAL fluid thrombin has been shown to 
promote fibroblast proliferation  131. In COPD, elevated procoagulant activity has been 
observed in the serum of patients with moderate to severe disease 133. Animal models of 
fibrosis have strengthened the connection between thrombin and fibrosis. Increased 
thrombin is found in the lungs of mice challenged with bleomycin and pharmacological 
inhibition of thrombin significantly reduced the collagen deposition 130.  
At the cellular level, thrombin has numerous biologic effects that are in addition to its role as a 
coagulation pathway proteinase. It has been shown to promote inflammation and fibrosis 
through inducing chemokine and growth factor production from fibroblasts. Many of the cell-
based activities of thrombin are mediated through a family of receptors termed proteinase-
activated receptors (PARs). PARs are G-protein coupled receptors (GPCR), with 4 known 
subtypes identified to date. A defining feature of these receptors is that they are activated by 
proteases that cleave a portion of the extracellular amino terminus to unmask a new N-
terminal sequence, which then functions as a tethered ligand that autoactivates the receptor. 
PAR-1-deficient mice are protected from bleomycin induced lung fibrosis 134. Further, PAR-2-
deficient mice had decreased eotaxin/CCL11 and reduced eosinophilia in the lungs following 
antigen challenge in an allergen sensitization and challenge model of asthma 135,136. 
Furthermore, thrombin and other PAR1 agonists promote the integrin-mediated activation 
latent TGF in a model of acute lung injury 98 . Thus, the local activation of TGF at sites of 
fibrosis may be enhanced by the coagulation cascade in both IPF and COPD.  
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6.4 Pentraxins 
Pentraxins comprise a highly conserved superfamily of cyclic pentameric proteins. These 
proteins interact with numerous ligands, including selected pathogens and apoptotic 
cells137, and are recognized by macrophages via mannose 6P and Fc gamma () receptors, 
ultimately leading to complement activation, pathogen recognition, and apoptotic cell 
clearance 138-140. Pentraxins are subdivided into the short pentraxins that include C-reactive 
protein (CRP) and serum amyloid P component (SAP, PTX2), and the long pentraxin 3 
(PTX3) 141,142. SAP appears to be uniquely involved in the resolution or repair phase of tissue 
injury via its modulator effects on resident and bone marrow derived collagen producing 
cells 76,143. SAP binds to Fc receptors144 and the anti-fibrotic activities of SAP have been 
shown to be mediated through Fc receptors143 which affect peripheral blood monocyte 
differentiation and activation states.  
SAP promotes the differentiation of M1 classically activated macrophages in a tuberculosis 
model of lung infection 145. We have recently demonstrated that SAP has prominent 
immunomodulatory effects on mouse macrophages, thereby providing a mechanism for its 
ability to prevent the development and reverse established experimental fungal airway disease 
75. Moreover, human SAP has been shown to potently inhibit the differentiation of monocytes 
into fibrocytes146 and it has consequently been used therapeutically in animal models to inhibit 
lung fibrosis and fibrosis in a number of organ sites. In addition, SAP causes an inhibition of 
the differentiation of peripheral blood mononuclear cells into CD45+/collagen I+ cells called 
fibrocytes76,146,147, as well as reducing M2 macrophage number 75,77.  
6.5 Matrix Metalloproteinases and Chitinases 
Active remodeling of the ECM is dependent on the coordinated activities of proteases and 
protease inhibitors 148,149. Fibroblasts generate metalloproteinases (MMPs), which are 
elevated in asthma and COPD (reviewed in 150). MMPs are a family of proteins that exert 
proteolytic activities on various proteins including ECM components and are thus central to 
ECM formation and organization 150. Tissue inhibitors of metalloproteinases (TIMP)s are 
endogenous inhibitors of MMPs that bind to the catalytic site on these proteinases 151. In IPF, 
MMP1, 2 and 9 were co-localized to the epithelium surrounding fibrotic lesions, whereas 
increased TIMP2 was also observed suggesting that the MMP activity may be inhibited and 
that the fibrotic region not degraded 152.  
Another family of enzymes associated with fibrosis and remodeling is the chitinase family. 
Chitinases are proteolytic enzymes that bind, but do not cleave chitin 153. Chitin is the main 
component of the insect exoskeleton, thought to be absent in human tissue. However, these 
proteins are postulated to play important, yet currently undefined roles in biology. The 
prototypic chitinase-like protein is derived from the chitinase 3 like 1 (Ch3l1) gene, called 
YKL40 in humans and BRP39 in mice. YKL40/BRP39 is a circulating regulator of apoptosis, 
and shown to have a role in M2 macrophage activation, TGF1 induction and tissue fibrosis 
154. An early report in asthmatics indicated that YKL40 is elevated in the circulation and is 
associated with asthma severity 155. Chitinolytic activity has also been demonstrated in COPD 
patients 156,157, as well as in models of cigarette smoke induced emphysema 157. Interestingly, 
BRP39 gene deficient mice have increased epithelial cell apoptosis and alveolar destruction in 
response to cigarette smoke, but worsened pathology in hyperoxia-induced lung injury which 
is a more acute ARDS-like model 157,158. Increased YKL40 has also been detected in the lungs 
and circulation of IPF patients, with levels correlating with survival 159,160. Thus, there is clear 
disease association with chitinase activity, however because of discrepancies in the different 
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animal models, whether these chitinases are promoting disease or uniquely serve as a marker 
of disease activity still requires further elucidation. 
7. Therapeutic options for targeting pro-fibrotic cells  
IPF is a disease that is driven by continual parenchymal ECM deposition, which reduces 
lung compliance and effective gas exchange. The fibrosis observed in the lungs of COPD 
patients predominates around small airways4,161 and may not be the main driving factor 
causing the loss in lung function and death. Emphysema and lung tissue destruction is often 
observed in COPD patients and honeycombing is a salient feature in IPF patient lungs 162. 
Overall this suggests an imbalance in repair processes within the lung and targeting the 
underlying pro-fibrotic mechanisms may impact COPD and IPF in a positive way. In IPF, 
the capacity of the lungs (FVC, forced vital capacity); as well as the efficiency of gas 
exchange (DLCO) may improve with a reduction in fibrosis. Both of these parameters are 
used clinically in IPF patients to measure lung function and monitor disease progression162. 
In COPD, anti-fibrotic strategies directed at the same cells and/or mediators may attenuate 
the obstructive nature in the airways and this may be the most discernible improvement in 
lung function. This would translate to an improvement in forced expiratory volume in a 
short time frame (FEV1). Again, FEV1 is commonly used in COPD patient management and 
is used to segregate patients into the various GOLD stages of disease4.  
As has been highlighted in this Chapter, monocytes and mesenchymal cells express a 
variety of receptor that can promote recruitment, proliferation or activation, as well as 
differentiation into other phenotypes (Fig. 2). In experimental mouse models of lung 
fibrosis, blocking fibrocyte recruitment through chemokine ligand/ receptor blockade 
significantly attenuated ECM deposition 54-56,163. However, these chemokine receptors are 
not uniquely expressed on fibrocytes164, so the anti-fibrotic effects observed following 
blockade of these G-protein coupled receptors might extend beyond impaired fibrocyte 
recruitment. Also, we have demonstrated that depletion of lung monocyte/ macrophages 
inhibits TGF-induced lung fibrosis, but has no effect on lung fibrocyte number, suggesting 
a redundant role for fibrocyte recruitment in promoting TGF-induced lung fibrosis 77.  
One other mechanism to consider in any therapeutic approach in pulmonary fibrosis is 
fibrocyte activation. A prototypic activator of fibrocytes, fibroblasts and myofibroblasts is 
TGF. Adenoviral-mediated over-expression of TGF in the lungs of mice or rats, or lung-
specific transgenic over-expression in mice induces significant lung pathology95,165,166. In the 
lung specific TGF over expression, active TGF is expressed by airway epithelial cells. At 
early timepoints following over-expression, apoptosis is observed, following by interstitial 
leukocyte accumulation and then increased collagen deposition, predominating around the 
airways and then gradually increasing in the parenchyma77,165,167. At later stages of lung-
specific TGF over-expression, alveolar collapse is observed77 whereas adenoviral TGF 
expression results in a prolonged, severe fibrosis95. These apparent chronic differences may 
be due to the initial extent of acute lung injury immediately following TGF over-
expression, in that transgenic mediated TGF induces extensive apoptosis, whereby 
blocking apoptosis inhibits subsequent fibrosis165. Blockade of TGF in experimental models 
of lung fibrosis through either antibody neutralization, receptor inhibition of TGF 
activation has been shown to attenuate lung remodelling 99,100,168-170. However, TGF1 gene 
deficient mice die within 3-4 weeks of age and demonstrate significant autoimmune 
pathologies, potentially due to the lack of immunoregulation in the absence of TGF 171,172. 
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Therefore direct neutralization of this target might have significant safety concerns in IPF or 
COPD patients.  
Other factors that work in concert with TGF- include IL4 and IL13. In order to examine the 
role of IL4- and IL13-responsive cells in pulmonary fibrosis, we have conducted preclinical 
studies using IL13 conjugated to a Pseudomonas exotoxin, IL13-PE173, which targets cells 
expressing the type 2 IL4 receptor and IL13R2. This protein-toxin conjugate selectively 
targets IPF fibroblasts because they express these receptor subunits, resulting in specific cell 
death. Moreover, in vivo use in a murine model of bleomycin-induced lung fibrosis showed 
that selective targeting of fibroblasts at the end stages or maintenance phase of fibrosis, 
attenuated remodelling. In contrast, IL13-PE delivered to the lung during the onset or 
initiation of disease had no therapeutic benefit173. This suggests that targeting these cells in 
established disease may allow for the resolution of lung pathology that is observed in 
chronic lung disease patients.  
Taken together, targeting stromal cells to dampen the extent of activation and the amount of 
ECM deposition, regardless of disease, or region within the lung may have an impact in 
lung function that can either halt disease progression or promote resolution and restoration 
of lung function. 
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